224 related articles for article (PubMed ID: 28638726)
41. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
Wang X; Liu Y
Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408
[TBL] [Abstract][Full Text] [Related]
42. PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients.
Absmaier M; Napieralski R; Schuster T; Aubele M; Walch A; Magdolen V; Dorn J; Gross E; Harbeck N; Noske A; Kiechle M; Schmitt M
Int J Oncol; 2018 Mar; 52(3):755-767. PubMed ID: 29328369
[TBL] [Abstract][Full Text] [Related]
43. Integration of whole-genome sequencing and functional screening identifies a prognostic signature for lung metastasis in triple-negative breast cancer.
Xie G; Yang H; Ma D; Sun Y; Chen H; Hu X; Jiang YZ; Shao ZM
Int J Cancer; 2019 Nov; 145(10):2850-2860. PubMed ID: 30977117
[TBL] [Abstract][Full Text] [Related]
44. Intra-tumoral microbial community profiling and associated metabolites alterations of TNBC.
Wang Y; Qu D; Zhang Y; Jin Y; Feng Y; Zhang H; Xia Q
Front Oncol; 2023; 13():1143163. PubMed ID: 37901331
[TBL] [Abstract][Full Text] [Related]
45. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
[TBL] [Abstract][Full Text] [Related]
46. The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer.
Mori H; Kubo M; Yamaguchi R; Nishimura R; Osako T; Arima N; Okumura Y; Okido M; Yamada M; Kai M; Kishimoto J; Oda Y; Nakamura M
Oncotarget; 2017 Feb; 8(9):15584-15592. PubMed ID: 28107186
[TBL] [Abstract][Full Text] [Related]
47. Gene expression in triple-negative breast cancer in relation to survival.
Wang S; Beeghly-Fadiel A; Cai Q; Cai H; Guo X; Shi L; Wu J; Ye F; Qiu Q; Zheng Y; Zheng W; Bao PP; Shu XO
Breast Cancer Res Treat; 2018 Aug; 171(1):199-207. PubMed ID: 29748761
[TBL] [Abstract][Full Text] [Related]
48. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.
Loi S; Michiels S; Salgado R; Sirtaine N; Jose V; Fumagalli D; Kellokumpu-Lehtinen PL; Bono P; Kataja V; Desmedt C; Piccart MJ; Loibl S; Denkert C; Smyth MJ; Joensuu H; Sotiriou C
Ann Oncol; 2014 Aug; 25(8):1544-50. PubMed ID: 24608200
[TBL] [Abstract][Full Text] [Related]
49. Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting.
García-Teijido P; Cabal ML; Fernández IP; Pérez YF
Clin Med Insights Oncol; 2016; 10(Suppl 1):31-9. PubMed ID: 27081325
[TBL] [Abstract][Full Text] [Related]
50. PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer.
Ren X; Wu H; Lu J; Zhang Y; Luo Y; Xu Q; Shen S; Liang Z
Cancer Biol Ther; 2018 May; 19(5):373-380. PubMed ID: 29336717
[TBL] [Abstract][Full Text] [Related]
51. c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer.
Ren X; Yuan L; Shen S; Wu H; Lu J; Liang Z
Tumour Biol; 2016 Aug; 37(8):11385-95. PubMed ID: 26968553
[TBL] [Abstract][Full Text] [Related]
52. Metabolite Profiling Reveals the Glutathione Biosynthetic Pathway as a Therapeutic Target in Triple-Negative Breast Cancer.
Beatty A; Fink LS; Singh T; Strigun A; Peter E; Ferrer CM; Nicolas E; Cai KQ; Moran TP; Reginato MJ; Rennefahrt U; Peterson JR
Mol Cancer Ther; 2018 Jan; 17(1):264-275. PubMed ID: 29021292
[TBL] [Abstract][Full Text] [Related]
53. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
[TBL] [Abstract][Full Text] [Related]
54. No association between triple-negative breast cancer and prognosis of patients receiving breast-conserving treatment.
Mu L; Liu Y; Xiao M; Liu W; Liu M; Wang X
Oncol Lett; 2017 Dec; 14(6):7862-7872. PubMed ID: 29250179
[TBL] [Abstract][Full Text] [Related]
55. Plasmacytoid Dendritic Cell (pDC) Infiltration Correlate with Tumor Infiltrating Lymphocytes, Cancer Immunity, and Better Survival in Triple Negative Breast Cancer (TNBC) More Strongly than Conventional Dendritic Cell (cDC).
Oshi M; Newman S; Tokumaru Y; Yan L; Matsuyama R; Kalinski P; Endo I; Takabe K
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33198125
[TBL] [Abstract][Full Text] [Related]
56. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
[TBL] [Abstract][Full Text] [Related]
57. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
58. Reassessment of Reliability and Reproducibility for Triple-Negative Breast Cancer Subtyping.
Yu X; Liu Y; Chen M
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681552
[TBL] [Abstract][Full Text] [Related]
59. Outcome following local-regional recurrence in women with early-stage breast cancer: impact of biologic subtype.
Braunstein LZ; Niemierko A; Shenouda MN; Truong L; Sadek BT; Abi Raad R; Wong JS; Punglia RS; Taghian AG; Bellon JR
Breast J; 2015; 21(2):161-7. PubMed ID: 25559656
[TBL] [Abstract][Full Text] [Related]
60. PPP2R2B downregulation is associated with immune evasion and predicts poor clinical outcomes in triple-negative breast cancer.
Li Z; Li Y; Wang X; Yang Q
Cancer Cell Int; 2021 Jan; 21(1):13. PubMed ID: 33407498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
